www.zejournal.mobi
May 17, 2024

Is Pfizer Using Children As Legal Human Shields To Get Full Authorization For COVID Vaccines?

Author : GreatGameIndia | Editor : Anty | January 14, 2022 at 03:23 AM

What the corporate press, Big Pharma, and the federal government are telling us is not true. Contrary to popular belief there is still no FDA approved COVID vaccine available in the United States today. And there are no plans to make one available in the near future. This begs the question, is Pfizer using children as legal human shields to get full authorization for its COVID vaccines?

Though it is hard to believe, it’s 100% true. And this reality hints at an incredible scandal within both Big Pharma and the U.S. Public Health bureaucracy.

On August 23, the FDA granted full approval for a COVID-19 vaccine to Pfizer-BioNtech for a specific product sold under the brand name Comirnaty. This product, Comirnaty, was fully authorized for the “prevention of COVID-19 disease in individuals 16 years of age and older.”

The landmark moment — the “full approval” endorsement from the FDA — was acclaimed by the Biden Administration and quickly leveraged to coerce millions into taking the shots.

But the fully approved version of Comirnaty itself has never made its way into the United States. Moreover, a separate product, considered under emergency use authorization (EUA), is the only “Pfizer shot” available in the United States.

As a reasonable explanation, early on, Pfizer and its government allies claimed that Comirnaty was not yet available because the EUA shots were still lining the shelves, and the FDA-approved version would soon be made available to all.

It has been over 4 months now, since full approval, but Comirnaty is still not being distributed.

The FDA has recognized Comirnaty as a “legally distinct” product with “certain differences,” but claims it does not impact safety or effectiveness of the shots. “Fact checkers” leverage the latter point of safety and efficacy to claim that people are still getting access to ingredients akin to the fully approved product.

The CDC continues to confirm that Comirnaty is “not orderable at this time.” Moreover, the CDC currently states that “Pfizer does not plan to produce any product with these NDCs (National Drug Codes) and labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution.”

Now, back to the trillion dollar EUA question.

Is Pfizer refusing to make the fully authorized version available, because doing so could open up Pfizer and BioNTech to legal liability issues?

Talking to The Washington Post in a previous “fact check,” Pfizer and an HHS spokesperson claimed that there’s no additional legal immunity benefits between the EUA product and Comirnaty. 

An EUA fully protects the drugmaker and grants zero legal recourse to the patient. This is one of the surefire protection measures that was bolstered by the PREP act to shield COVID companies from liability.

Now, here’s where it all gets very nefarious.

Due to a law passed during the Reagan Administration, the drug makers must first secure full approval for the children’s version of their shot in order to be granted more robust legal liability protection for their vaccines.

The National Childhood Vaccine Injury Act (NCVIA), which was passed into law in 1986, provides a legal liability shield to drug manufacturers if they receive full authorization for all ages.

Now is this the reason why Pfizer is seeking approval for children so that it can protect itself from lawsuits? 

Surely, there’s also a monetary incentive at play, but maybe there’s another reason why Moderna, Pfizer and others are working relentlessly to authorize their products for children, who face near-zero risk from COVID-19, but continue to showcase alarming side effects from the vaccine.

Pfizer receives an extensive, additional layer of protection, if Comirnaty becomes available for all ages.


Read More :


- Source : GreatGameIndia

Send via email :

Comment

Send your comment via :



Close

Search
Like Our Site?
(34)
Latest Articles
Most Read Articles
Loading...
Loading...
Loading...

Email Subscribe

Received our newsletter, we send it to your email

  


Close